Search

Bio-Techne Corp

Gesloten

SectorGezondheidszorg

71.93 0.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

71.51

Max

71.83

Belangrijke statistieken

By Trading Economics

Inkomsten

13M

51M

Verkoop

16M

311M

K/W

Sectorgemiddelde

103.826

62.58

EPS

0.53

Dividendrendement

0.44

Winstmarge

16.392

Werknemers

3,100

EBITDA

21M

99M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-6.34% downside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

0.44%

2.19%

Volgende Winsten

5 aug 2026

Volgende dividenddatum

28 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.6B

11B

Vorige openingsprijs

71.54

Vorige sluitingsprijs

71.93

Nieuwssentiment

By Acuity

65%

35%

296 / 340 Rangschikking in Healthcare

Bio-Techne Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 jul 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Peer Vergelijking

Prijswijziging

Bio-Techne Corp Prognose

Koersdoel

By TipRanks

-6.34% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 67.09 USD  -6.34%

Hoogste 73 USD

Laagste 50 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bio-Techne Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

14 ratings

1

Buy

13

Hold

0

Sell

Sentiment

By Acuity

296 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat